SeptRx has concluded enrolment of the first 20 patients in its ongoing InterSEPT clinical trial at Sankt Katharinen Hospital in Frankfurt, Germany.

The prospective multicentre single-arm InterSEPT trial will evaluate the safety and efficacy of the SeptRx Intrapocket PFO Occluder as a treatment for percutaneous transcatheter closure of a heart defect known as patent foramen ovale

The findings from the InterSEPT trial will be used to apply for European approval for the SeptRx Intrapocket PFO Occluder, which is designed to close "hole in the heart" defects and lower the risk of stroke.

In a previous successful 11-patient first-in-human clinical trial, the SeptRx Intrapocket PFO Occluder demonstrated 100% closure and 100% safety following three years of treatment.

SeptRx CEO Scott Russell said earlier excellent patient outcomes from the first-in-human study will support the expansion of the trial into additional centres and the introduction of a larger 19mm device into the trial.

In June 2011, the company received $2.7m in Series A financing from Nitinol Devices & Components, to advance SeptRx IPO through CE mark registration.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The SeptRx Intrapocket PFO Occluder is not approved for sale in any regulatory jurisdiction, and it is not yet available for investigational use or commercial sale in the US.